The Neuroprotective Mechanism of Lithium after Ischaemic Stroke.

doi:10.21203/rs.3.rs-715301/v1

Download PDF

Research Article

The Neuroprotective Mechanism of Lithium after Ischaemic Stroke.

https://doi.org/10.21203/rs.3.rs-715301/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 03 Feb, 2022

Read the published version in Communications Biology →

Version 1

posted

You are reading this latest preprint version

Stroke causes degeneration and death of neurones leading to the loss of motor function and frequent occurrence of cognitive impairment and depression. Lithium (Li⁺), the archetypal mood stabiliser, is neuroprotective in animal models of stroke, albeit underlying mechanisms remain unknown. We found that Li⁺ inhibits activation of nucleotide-binding oligomerisation domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasomes in the middle cerebral artery occlusion (MCAO) stroke model in mice. This action of Li⁺ is mediated by two signalling pathways of AKT/GSK3β/β-catenin and AKT/FoxO3a/β-catenin which converge in suppressing the production of reactive oxygen species (ROS). Using immunocytochemstry, MRI imaging, and cell sorting with subsequent mRNA and protein quantification we demonstrate that Li⁺ decreases the infarct volume, improves motor function, and alleviates associated cognitive and depressive impairments. In conclusion, this study reveals molecular mechanisms of Li⁺ neuroprotection during brain ischaemia thus providing the theoretical background to extend clinical applications of Li⁺ for treatment of ischemic stroke.

Neurobiology of Disease

Cell Survival and Cell Death

ischaemic stroke

lithium

neuroprotection

NLRP3 inflammasome

reactive oxygen species

oxidative stress

uncoupling protein 2

β-catenin

Ischaemic stroke is a severe life-threatening disease, accounting for 75–80% of all strokes, which have been the second leading cause of death worldwide^1–3. Several treatments aimed to restore blood flow (reperfusion), such as intravenous thrombolysis and thrombectomy, have been developed in recent decades⁴. Nevertheless, progressive degeneration and death of neurones responsible for loss of brain function remains difficult-to-solve issue for treatment and rehabilitation. Cognitive impairment and depression are common stroke complications^5,6, with the occurrence rate close to 30%^7,8. Improving neurological outcome after an ischaemic stroke is a major societal priority, which has attracted much attention of clinical and basic research, government funding agencies, and industry. Majority of stroke neuroprotectants effective in rodents research have failed to translate into clinical practice^9,10. Repurposing market-approved drugs for treatment of the cerebral ischaemia therefore represents a viable strategy.

Lithium (Li⁺) was first used in clinical practice for dissolving urinary calculi¹¹; whereas first psychiatric usage of Li⁺ as anticonvulsant, hypnotic and anti-mania drug has been reported in 1870es^12,13. The modern era of Li⁺ usage in psychiatry begun in1952 when Li⁺ therapy was considered to be a useful alternative to then all-popular electroconvulsive therapy^14,15. Therapy with Li⁺ is effective in treatment of acute mania and acute depression as well as prevention of recurrent mania and depression ^16,17. In recent two decades, Li⁺ has been reported to exert neuroprotection in animal models of stroke, neurodegenerative diseases, spinal cord injury and other impairments of the central nervous system¹⁸. In addition, Li⁺ protects neurones against glutamate excitotoxicity, seizures, and neurotoxic attacks¹⁹. The effective and safe dose range for Li⁺ in serum is narrow ranging between 0.6 and 1.0 mM; at concentrations exceeding 1.5 mM Li⁺ is toxic. Serum Li⁺ levels of 1.5–2.0 mM produce mild and reversible toxicity at kidney, liver, heart, and secretory glands. Serum levels above 2 mM may be associated with neurological symptoms, including cerebellar dysfunction¹⁷. Narrow safety range limits the neuroprotective usage of Li⁺ for ischaemic stroke²⁰, as well as for associated dementia or depression symptoms ^21–23.

Mounting evidence has demonstrated that NLRP3 (nucleotide-binding oligomerisation domain-like receptor family pyrin domain-containing 3) inflammasome plays a prominent role in the pathogenesis and progression of ischaemic stroke^24–26. Many aspects of the biology of NLRP3 inflammasome in stroke remain, however, unknown. While numerous activators of the NLRP3 inflammasome have been identified, the underlying mechanism of activation has not been fully elucidated. Existing hypotheses include interaction with reactive oxygen species (ROS), lysosomal rupture, and potassium efflux^27,28. Accumulation of ROS and oxidative stress contribute to brain injury after ischaemic stroke, with suppression of ROS overproduction being considered as a therapeutic strategy²⁹.

The NLRP3 inflammasome is a multiprotein complex, assembled from the adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC) and inflammatory caspase 1 (cysteine-dependent aspartate-directed protease 1). The major function of NLRP3 inflammasome is to recognise a wide range of danger signals associated with lesions to nervous tissue. Through recognition of damage-associated molecular patterns, the NLRP3 inflammasome, with its ASC and pro-caspase 1 components, promotes the activation of caspase 1 and the processing of cytoplasmic targets, including IL-1β and IL-18³⁰. During this process, gasdermin D (GSDMD), a physiological substrate of the canonical inflammasome pathway and pyroptosis executor is recruited to the NLRP3 inflammasome and cleaved by pro-caspase-1 and matured caspase-1. It is not necessary for ASC to cleave GSDMD³¹, N-terminal fragment of caspase-1-cleaved GSDMD approaches the plasma membrane and oligomerises to form plasma membrane pores, thus triggering pyroptosis and promoting maturation and release of IL-1β³². Accumulating evidence suggests that NLRP3 inflammasome plays an essential role in the pathogenesis of ischaemic stroke ²⁴⁻²⁶, however, the cell-specific expression and distribution of NLRP3 inflammasome is not fully characterised. There are indications for NLRP3 expression in microglia and endothelial cells but not in neurones³³, as well as data showing an increase in NLRP3 inflammasome proteins, IL-1β and IL-18 in the ipsilateral neurones of cerebral ischaemic and reperfused mice as well as in neurones from the postmortem stroke patients brain tissue³⁴.

Li⁺ inhibits activation of NLRP3 inflammasome following ischaemic injury

We modelled ischaemic injury by 1 hour middle cerebral artery occlusion (MCAO) followed with reperfusion. The following experimental groups were established: sham + normal solution (NS) group (control), sham + lithium chloride group (LiCl), MCAO + NS group (MCAO) and MCAO + LiCl group. The details of experimental design are shown in Supplementary Fig. 1. We intraperitoneally (i.p.) injected LiCl at 1 mmol/kg/day for 5 days, which corresponds to serum Li⁺ concentration of ~ 0.8 mM and in cerebral tissue concentration of ~ 0.5 mM³⁵. When comparing with control group, the immunofluorescence of NLRP3 increased specifically in neurones of ischaemic ipsilateral cortex (p < 0.001); we did not detect any increase in NLRP3 immunofluorescence in astrocytes and microglia (Fig. 1A-1L). An increase in NLRP3 in neurones of MACO-subjected cerebral cortex was effectively suppressed by administration of LiCl at 1 mmol/kg/day (p < 0.001; Fig. 1D). The immunofluorescence of caspase-1 and gasdermin D (GSDMD) were both increased by ischaemia-reperfusion in cortical neurones, astrocytes and microglia (p < 0.001; Fig. 1D, 1H and 1L). Treatment with Li⁺ significantly decreased ischaemia-induced elevation in immunofluorescence of caspase-1 and gasdermin D (GSDMD) in astrocytes and microglia as compared with MCAO group (p < 0.001; Fig. 1B-1D, 1F-1H and 1J-1L). In summary, ischaemia-reperfusion increased NLRP3 only in neurones, whereas caspase-1 and GSDMD were increased also in astrocytes and in microglia. We further quantified proteins in the populations of neurones (FACS sorted from Thy1-YFP transgenic mice), astrocytes (from GFAP-GFP transgenic mice) and microglia (FACS sorted Iba-1 positive cells of wild type mice). When compared to a control, protein expression of NLRP3, caspase-1 and GSDMD increased in neurones (p < 0.001), whereas expressions of caspase-1 and GSDMD increased in astrocytes and microglia (p < 0.001; Supplementary Fig. 2A-2D) in the ipsilateral cortex of MCAO mice. Treatment with Li⁺ effectively inhibited increased expressions of NLRP3, caspase-1 and GSDMD as compared with MCAO group (p < 0.001; Supplementary Fig. 2A-2D). Protein levels of pro-caspase-1 and ASC were not significantly changed in MCAO mice with or without Li⁺ administration (Supplementary Fig. 2E and 2F).

Signalling pathways involved in Li⁺ neuroprotection

As compared with control, exposure to MCAO decreased the phosphorylation of GSK3β at Ser9 in the extract of the cytoplasm of ipsilateral cortex (p < 0.001). Τreatment with Li⁺ increased the phosphorylation of GSK3β Ser9 as compared with MCAO (p < 0.01), whereas selective AKT inhibitor (LY294002 at 12.5 mg/kg) abolished action of Li⁺ on the phosphorylation of GSK3β Ser9 (Fig. 2A and 2B). When compared with control, the expression of GSK3β did not change significantly in the MCAO mice with or without Li⁺ treatment (Fig. 2A and 2C). Treatment with Li⁺ activates AKT phosphorylation thus inhibiting GSK3β activity, which, in turn, alleviates the over-activation of GSK3β following ischaemia-reperfusion (Fig. 2A and 2B). Of note, activation of GSK3β phosphorylates β-catenin resulting in proteosomal degradation³⁶, while stabilised β-catenin promptly translocates into the nuclei³⁷. We found a significant decrease in cytoplasmic β-catenin in cytoplasm following ischaemia-reperfusion (p < 0.001; Fig. 2A and 2D), likewise, β-catenin was reduced in the nuclear fraction (p < 0.001; Fig. 3A and 3B). When compared with MCAO group, Li⁺ increased β-catenin in cytoplasm and in nucleus, while administration of 12.5 mg/kg LY294002 inhibited Li⁺-induced elevation of β-catenin in cytoplasm and in nucleus (p < 0.001; Fig. 2D and 3B). It is known that AKT can phosphorylate transcription factor forkhead box, class O3a (FoxO3a), which results in the redistribution of FoxO3a from the nucleus to the cytoplasm³⁸. As compared with control group, exposure to ischaemia-reperfusion decreased the level of FoxO3a in the cytoplasm (p < 0.001; Fig. 2A, 2E and 2F), but increased its presence in the nucleus (p < 0.001; Fig. 3A and 3C). Phosphorylation of FoxO3a was also decreased in the cytoplasm extracted form the cortex of MCAO treated mice as compared with sham plus NS group (p < 0.001; Fig. 2E and 2F). Treatment with Li⁺ in control group also increased cytoplasmic FoxO3a and p-FoxO3a, while FoxO3a in the nucleus was decreased (Fig. 2E, 2F and 3C). Treatment with PI3 kinase/AKT inhibitor LY294002 completely eliminated effects of Li⁺ on re-distribution of FoxO3a (Fig. 2E, 2F and 3C). Ischaemia-reperfusion also decreased the co-immunoprecipitation of transcription factor TCF4 with β-catenin (β-catenin and TCF4 complex is known to regulate several dowstreams genes³⁹ as compared with sham group (p < 0.001; Fig. 3D and 3E), whereas Li⁺ enhanced linkage of TCF4 with β-catenin (p < 0.001; Fig. 3D and 3E), again this effect was abolished by LY294002 (Fig. 3D and 3F).

Protein expression of STAT3 as well as ratio of p-STAT3/STAT3 were decreased by ischaemia-reperfusion (p < 0.001; Fig. 4A-4C). Administration of Li⁺ increased the expression and phosphorylation of STAT3 in both sham (p < 0.05) or MCAO group (p < 0.001; Fig. 4A-4C). Enhanced expression and phosphorylation of STAT3 induced by Li⁺ was abolished by LY294002 and by the coupling blocker of the complex of β-catenin and TCF4, PKF115584 (Fig. 4A-4C). Ischaemia-reperfusion significantly reduced protein and mRNA expression of uncoupling protein 2 (UCP2, the cationic carrier protein in mitochondrial intima). Treatment with Li⁺ increased UCP2 expression at protein and mRNA level in both control and MCAO group (p < 0.001; Fig. 4D-4F). These effects of Li⁺ were suppressed by LY294002 and a selective inhibitor of STAT3, WP1066, (Fig. 4D-4F). Finally, MCAO-elevated ROS in the extracted mitochondria from the ischaemic ipsilateral cortex were also decreased by Li⁺, and this effect was antagonised by LY294002 and WP1066 (Fig. 4G).

Treatment with Li⁺ alleviated MCAO-induced increase in protein expressions of NLRP3, caspase-1 and GSDMD; these effects were antagonised by LY294002, PKF115584, WP1066 and UCP2 inhibitor genipin (Supplementary Fig. 3A-3D). Protein expressions of pro-caspase-1 and ASC were not significantly modulated by MCAO or the administration of Li⁺ (Supplementary Fig. 3E and 3F). In contrast, production of IL-1β and IL-18 by NLRP3 inflammasome after ischaemia-reperfusion was reduced by Li⁺, which was prevented by LY294002 and WP1066 and genipin (Supplementary Fig. 3G and 3H).

The neuroprotective effects of Li⁺ on ischaemic stroke

Neuronal apoptosis in the ischaemic penumbra in MCAO mice was significantly alleviated by Li⁺ (p < 0.001; Fig. 5A). Likewise, the ischaemic volume (assessed by staining with 1% 2,3,5-triphenyltetrazolium chloride, TTC) was significantly reduced by Li⁺ (p < 0.001; Fig. 5B). Similar decrease in ischaemic region in the presence of Li⁺ was observed in T2-weighted magnetic resonance (MRI) images (Fig. 5C).

Treatment with Li⁺ improved the 4-week dynamic of neurological scores of MCAO mice (Fig. 6A). In particular, Li⁺ significantly improved motor activities of MCAO mice as revealed by rotating rod and pole tests; these improvements were antagonised by LY294002, PKF115584, WP1066 and genipin (Fig. 6B and 6C). Similarly, Li⁺ improved MCAO-affected outcomes of open field test t (Fig. 6D), and decreased the number of work and reference memory errors recorded in 8 arms maze test (Fig. 6E). Finally, Li⁺ alleviated depressive-like behaviours induced by MCAO, as demonstrated by sucrose preference and tail suspension test (Fig. 6F); Li⁺ also reduced the immobility time elevated in MCAO mice (Fig. 6G). All these effects of Li⁺ were abolished by LY294002, PKF115584, WP1066 and genipin (Fig. 6B-6G).

In this study we dissected molecular mechanisms of Li⁺ neuroprotection. We discovered that Li⁺ effectively suppresses activation of NLRP3 inflammasome in the ischaemic cortex and improves impaired behaviours. At a molecular level, Li⁺ inhibits activation of GSK3b by stimulating AKT, inactivated GSK3b subsequently decreases degradation of cytoplasmic b-catenin, which is transferred into the nucleus to form b-catenin/TCF4 complexes. At the same time AKT, stimulated by Li⁺, increases phosphorylation of cytoplasmic FoxO3a, which results in FoxO3a exit from the nucleus. Nuclear FoxO3a competes with binding sites of b-catenin with TCF4, and therefore the decrease of nuclear FoxO3a induced by Li⁺, further enhances formation of b-catenin/TCF4 complexes. These complexes phosphorylate STAT3, which promotes expression of UCP2. The up-regulation of UCP2 decreases production of ROS in mitochondria, which counteracts the activation of NLRP3 inflammasome induced by ischaemia and reperfusion (Fig. 7).

Our study suggests that Li⁺ acts through signalling pathways responsible for neuroinflammation and pyroptosis, in particular interfering with ischaemia and reperfusion-induced activation of NLRP3 inflammasome. Activation of NLRP3 inflammasome was detected only in neurones, whereas increase in pyroptosis executor gasdermin D has been identified in the neurones, astrocytes and microglia of ischaemic cortex. Administration of Li⁺ effectively suppressed activation of NLRP3 inflammasomes and neuronal apoptosis. However, increase in NLRP3 protein expression induced by ischaemia and reperfusion in the cortex only occurred in neurones and not in astrocytes or microglia. Our data highlight that activated patterns of NLRP3 inflammasome induced by ischaemia and reperfusion are different between neurones and glial. After ischaemia-reperfusion, activation of caspase-1 recruitment of GSDMD were NLRP3-independent in astrocytes and in microglia. Similarly, in macrophages and neurotrophils, NLR-family CARD-containing protein 4 (NLRC4) is reported to activate caspase-1 and trigger pyroptosis⁴⁰.

FoxO3a is a transcriptional target for mood disorder treatments, while FoxO3a-deficient mice present antidepressant-like behaviours⁴¹. In cultured embryonic kidney (HEK 293) and SH-SY5Y neuroblastoma cells, the antidepressive action of Li⁺ involves reduced FoxO3a transcription and decreased protein levels both in cytosol and nucleus⁴². We observed positive effects of Li⁺ not only on cognition and motor abilities, but also on despair-like behaviours induced by ischaemia-reperfusion. We found that Li⁺ acting through AKT pathway enhances the phosphorylation of FoxO3a, which promotes the translocation of FoxO3a from nucleus into cytoplasm thus suppressing competition of FoxO3a with TCF4 for the binding points of b-catenin in nucleus. It is known that Li⁺ restores compromised blood-brain barrier (BBB) by up-regulating endothelial Wnt/b-catenin signalling⁴³. Increase in b-catenin/TCF4 complex formation induced by Li⁺ accelerates the expression and phosphorylation of STAT3 in the nucleus (Fig. 2). Furthermore, WP1160, a STAT3 agonist, decreased NLRP3 expression by reducing the downstream STAT3 activation in SH-SY5Y neuroblastoma⁴⁴. Our previous research also demonstrates that the increased activation of STAT3 by fluoxetine and leptin restores the sleep deprivation-induced depressive-like behaviours by inhibiting an activation of NLRP3 inflammasome in astrocytes^45,46. In the present study we also show that Li⁺ inhibits activation of NLRP3 inflammasome and improves motor behaviour, cognition and depression by stimulating STAT3 (Fig. 6and supplementary Fig. 3). This inhibition of STAT3 results in the up-regulation of expression of UCP2 (Fig. 2). In UCP2-knockout mice, activation of NLRP3 inflammasome is enhanced by increased ROS production which exacerbates detrimental effects of ischaemia and reperfusion⁴⁷. To conclude, our study supports the clinical application of Li⁺ in ischaemia and stroke.

Materials

Primary antibody of ASC (sc-365611), caspase-1(sc-56036), b-catenin (sc-59737) and p-STAT3 (sc-81523) were purchase from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Primary antibody of NLPR3 (ab214185), pro-caspase-1 (ab179515), GFAP (ab48050), Iba-1 antibody used for FACS (ab178846) and secondary antibody Alexa Fluor 555 goat anti rabbit (ab150074) were purchased from Abcam (Cambridge, MA, USA). Primary antibody of Foxo3a (720128), p-GSK3b Ser9 (MA5-14873), UCP2 (PA5-80203), NeuN (PA5-78693) and Alexa Fluor-conjugated 488 secondary antibody used for FACS (A-11001) were purchased from Thermo Fisher Scientific (Waltham, MA USA). Primary antibody of GSK3b (22104-1-AP), TCF4 (22337-1-AP) and STAT3 (10253-2-AP) were purchased from Proteintech (Wuhan, Hubei, China). Primary antibody of b-actin (E021020), Histone H3 (E021130), HSP60 (A200659) and secondary antibody HRP-labelled Goat anti Mouse (E030110) and HRP-labeled Goat anti Rabbit (E030120) were purchased from Earthox (Millbrae, CA, USA). LY294002 was from PeproTech (1543664, Rocky Hill, NJ, USA). PKF115584 was from Novartis (Basel, Switzerland), WP1066 (S2796) and geninpin (S2412) was from Selleck Chemicals (Houston, Texas, USA). Iba-1 antibody used for immunofluorescence (019-19741) was purchased from Wako Chemicals (USA) Chemicals for the preparation of cell-sorting medium, p-Foxo3a antibody (PA5-37578) and Alexa Fluor-conjugated 488/555 secondary antibody (A21202, A31570) were from Gibco Life Technology Invitrogen (Grand Island, NY, USA). 2,3,5-triphenyltetrazolium chloride (T8877) was from Sigma-Aldrich (St. Louis, Missouri, USA). TUNEL apoptosis detection kit (11772457001) was purchased from Roche-Sigma (USA). The ROS assay kit (BB-470532) was purchased from BestBio (Shanghai, China). The quantitative PCR (RR820A and RR047A) was purchased from TaKaRa Bio (Kusatsu, Japanese). The ELISA kit for IL-1β (88-7013) and IL-18 (88-50618) were purchased from Thermo Fisher Scientific (Waltham, MA USA). The mitochondria extraction kit (BB-470532) was purchased from BestBio (Shanghai, China).

Animals

The wild type C57BL/6 mice (#000664), FVB/N-Tg(GFAP-eGFP)14Mes/J (#003257) and B6.Cg-Tg(Thy1-YFP)HJrs/J (#003782) transgenic mice were all purchased from the Jackson Laboratory (Bar Harbor, ME, USA). The animals were raised in standard housing conditions (22 ± 1℃; light/dark cycle of 12/12h), with water and food available ad libitum. All experiments were performed in accordance with the US National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 8023) and its 1978 revision, and all experimental protocols were approved by the Institutional Animal Care and Use Committee of China Medical University, No. [2020]102.

Middle cerebral artery occlusion (MCAO)

MCAO was used to model ischaemic stroke in mice. The male C57BL/6 mice, FVB/N-Tg(GFAP-eGFP)14Mes/J mice or B6.Cg-Tg(Thy1-YFP)HJrs/J transgenic mice (aged 10-12 weeks; weight of 25-35 g) were anesthetised with ketamine (80 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.) and placed on their backs to expose the neck area. A 1.5 cm incision was made in the middle of neck. The right common artery (CCA) was exposed. The external arteries (ECA) and internal carotid arteries (ICA) were isolated from CCA. The distal ECA was tied off and the CCA was clipped by a bulldog clamp. The ECA was opened by arteriotomy and a 5-0 nylon monofilament (181022, LingQiao, Ningbo, Zhejiang, China) was inserted and gently advanced upwards to the ICA. The insertion was stopped when resistance was felt. After 60 min of occlusion, the monofilament was withdrawn to allow for reperfusion. The mice were dislocated executed to collect tissues, after building MCAO models with reperfusion 5 or 28 days. In sham groups, the carotid arteries were exposed and the skin was sutured. Body temperature of mice was maintained and mice were individually housed after full recovery from anaesthesia⁴⁸.

Experimental design and drug administration

The wild type or transgenic mice were randomly segregated into sham plus normal solution (NS) group (control), sham plus lithium chloride group (LiCl), MCAO plus NS group (MCAO) and MCAO plus LiCl group. 30 minutes before the surgery of MCAO, some mice in MCAO groups were randomly chosen to be intraperitoneal injected with 12.5 mg/kg/day LY294002 (AKT inhibitor), 0.2 mg/kg/day PKF115584 (antagonist of β-catenin/TCF4 complex), 30 mg/kg/day WP1066 (STAT3 inhibitor) or 2.5 mg/kg/day geninpin (UCP2 inhibitor). After 30 minutes, mice with or without injected inhibitors were subjected to MCAO or treated with sham; 30 min after surgery 1 mmol/kg/day LiCl or normal saline (NS) were randomly intraperitoneally injected. After 60 minutes of ischaemia, the middle cerebral artery was reperfused, The injection of all reagents was repeated once a day for 5 days. Subsequently, 6 mice form each group were sacrificed by cervical dislocation for histology and biochemistry. Remaining mice were used for behavioural tests; detailed experimental design is shown in Supplementary figure 1.

Immunofluorescence (IF)

To identify the levels of NLRP3, caspase-1, GSDMD in three nerve cells (neurones, astrocytes and microglia) in ischaemic penumbra area of cerebral cortex. The anaesthetised mice were myocardially perfused with 4% paraformaldehyde (PFA) for 15 minutes. The collected brains were fixed by immersion in 4% paraformaldehyde and cut into 60 μm slices. The slices were permeabilised by incubation for 1 hour with donkey serum. Primary antibodies against NLRP3, caspase-1 or GSDMD were used at 1:200 dilution, against glial fibrillary acidic protein (GFAP), NeuN or Iba1 was used at 1:200 dilution. And nuclei were stained with marker 4’, 6’-diamidino-2-phenylindole (DAPI) at 1:1000 dilution. The incubation with the primary antibodies were overnight at 4 °C and then donkey anti-mouse or anti-rabbit Alexa Fluor 488/555 conjugated secondary antibodies were incubated for 2 hours at room temperature. Images were captured using a confocal scanning microscope (DMi8, Leica, Wetzlar, Germany)⁴⁹.

Co-immunoprecipitation (Co-IP)

We used technologies of co-immunoprecipitation and subsequent western blotting to check the conjunction level between TCF4 and β-catenin. For immunoprecipitation of TCF4, lysates of mice cerebral cortex (500 μg) were incubated with 20 μg of b-catenin antibody for overnight at 4 °C. Then, 200 μl of washed protein G-agarose bead slurry was added, and the mixture was incubated for another 2 hours at 4 °C. The agarose beads were washed three times with cold phosphate buffer solution (PBS) and collected by pulsed centrifugation (5 seconds in a microcentrifuge at 14,000×g), the supernatant was drained off, and the beads were boiled for 5 minutes. Thereafter, the supernatant was collected by pulsed centrifugation. Then, the protein content was determined by the Bradford method⁵⁰using bovine serum albumin (BSA) as the standard again. 100 μg immunoprecipitates were subjected to 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and followed the next measurements of western blotting⁴⁹.

Western blotting

Protein expressions of NLRP3, pro-caspase-1, caspase-1, GSDMD, p-GSK3β Ser9, GSK3β, β-catenin, TCF4, p-STAT3, STAT3, UCP2, HSP60, β-actin and Histone H3 were analysed with Western blot performed 5 days after MCAO or sham surgeries. The samples of ischaemic ipsilateral cortex containing 100 μg of protein were added 10% SDS-polyacrylamide gel electrophoresis. After electrophoretic separation the gels were transferred to polyvinylidene fluoride (PVDF) membranes, the membranes were blocked by 5 % skimmed milk powder for 1 hour, and incubated overnight with the primary antibodies, specific to: NLRP3 at 1:1000 dilution, pro-caspase-1 at 1:1000 dilution, caspase-1 at 1:1000 dilution, GSDMD at 1:1000 dilution, p-GSK3β Ser9 at 1:1000 dilution, GSK3β at 1:3000 dilution, ASC at 1:1000 dilution, β-catenin at 1:1000 dilution, p-Foxo3a at 1:1000 dilution, Foxo3a at 1:1000 dilution, TCF4 at 1:1000 dilution, STAT3 at 1:3000 dilution, p-STAT3 at 1:1000 dilution, UCP2 at 1:1000 dilution, HSP60 at 1:3000 dilution, β-actin at 1:3000 dilution and Histone H3 at 1:3000 dilution. After washing, specific binding was detected by horseradish peroxidase-conjugated secondary antibodies. Staining was visualised by electrochemiluminescence (ECL) detection reagents and were analyzed with an Electrophoresis Gel Imaging Analysis System (MF-ChemiBIS 3.2, DNR Bio-Imaging Systems, Israel). Band density was measured with Window AlphaEaseTM FC 32-bit software⁵¹.

Real-time PCR

To measure the mRNA of UCP2, the RNA of cerebral cortex was extracted by Trizol reagent (Invitrogen, Carlsbad, CA, USA). Total RNA was reverse transcribed to cDNA by using a reverse transcription reagent kit (Takara, Otsu, Shiga, Japan) in a Robo-cycler thermocycler. Real-time PCR was performed with the LightCycler 480 SYBR Green I Master kit and the products were detected using an a LightCyler 480 instrument. The sequences of Real-time PCR primers used for mRNA quantification were as follows: 5′-TAGTGCGCACCGCAGCC-3′ and 5′-AGCTCATCTG-GCGCTGCAG-3′ for mouse UCP2 and 5′-TGGTGCCAAAAGGGTCATCTCC-3′ and 5′-GCCAGCCCCAGCATCAAAGGTG-3′ for mouse GAPDH. Relative genomic expression was calculated by the 2^−ΔΔCt method^52,53.

The proteins extraction of cytoplasm and nucleus

The cytoplasm or nuclear proteins were extracted by using the protein extraction kit, according to the manufacturer’s protocol. The collected cortex was cut into small pieces and placed in new pre-cooling microcentrifuge tubes. Then, 200 μl mixture solution of cytoplasmic extraction reagent A and B was added, and the tissues were grinded into homogenate. All sample tubes were placed in an ice-bath and rest for 10 minutes. 10 μl cytoplasmic extraction reagent B was added again and the sample was vortexed and centrifugated at 15,000×g, 4 °C for 5 minutes. After centrifugation, the cytoplasmic extract in supernatant was immediately transferred to a new pre-cooled tube, and the sediment was suspended with 50 μl nuclear extraction reagent. The sediment was vortexed for 30 seconds. Then, the sample tubes were put back into the ice bath and vortexed for 30 seconds every 2 minutes, keeping 30 minutes. Centrifuging the sample tubes at 15,000×g, 4 °C for 10 min, the supernatant was obtained as nuclear extract.

Mitochondria isolation

Mitochondria isolation and fractionation was conducted by using the mitochondria extraction kit, according to the manufacturer’s protocol. Fresh cerebral cortex separated from mice brain were homogenised with a glass homogeniser in cold lysis buffer. Then, the homogenates were centrifuged at 800×g, 4 °C for 5 min. After centrifugation, the supernatant was slowly transferred to a new pre-cooled tube, which pre-added with 0.5 ml extraction reagent A. To centrifuge the sample tubes at 15,000×g, 4 °C for 10 min, the supernatant was obtained as cytoplasm extract. The sediment was suspended with 200 ml wash buffer, then centrifuged at 15,000×g, 4 °C for 10 min again. To dispose the supernatant, the sediment was obtained as mitochondria and resuspended with 100 μl storage buffer and kept under -80 °C.

ROS detection

To assay the ROS level, a commercial ROS assay kit was used and operated as the protocols. To conduct the experiment, cerebral cortex of mice was homogenised with 1 ml buffer reagent A by using a glass homogeniser. The homogenates were centrifuged at 15,000×g, 4 °C for 10 min. 190 μl supernatant of tissue homogenates and 10 μl fluorescence dye 2′,7′-dichlorodihydrofluorescin diacetate (DCFH-DA) were co-incubated in 96 well plate for 30 minutes at 37 °C. Finally, the fluorescence intensity of each well was measured using a fluorescence microplate reader (Infinite M200 Pro, Hombrechtikon, Swiss). For fluorescence detection, the excitation wavelength was at 488 nm, and the emission peak was examined at 525 nm.

ELISA assays

Cytokine levels of IL-1b and IL-18 in cortex were determined in duplicate following ELISA assay instructions provided by the manufacturers. The optical density (OD) of each microwell was measured at 450 nm using a microplate reader. The minimum detection limits for mouse IL-1b and mouse IL-18 were 31.2 pg/ml and 8 pg/ml, respectively.

Sorting neural cells through fluorescence activated cell sorter (FACS)

To measure the protein expressions of NLRP3 inflammasome and GSDMD, B6.Cg-Tg(Thy1-YFP)HJrs/J transgenic mice were used for isolating neurones, FVB/N-Tg(GFAPGFP)14Mes/J mice were used for isolating astrocytes, wild type mice were used for sorting microglia by using Iba-1 primary antibody and the associated Alexa Fluor 488 secondary antibody. A single-cell suspension from the cortex was prepared. The cortices from three mice were pooled for one sample. Wavelengths of 488 nm and 530/30 nm were used for GFP or YFP excitation and emission, respectively. The labelled cells were sorted and collected using the BD FACSAria Cell Sorting System (35 psi sheath pressure, FACSDiva software S/W 2.2.1; BD Biosciences, San Jose´, CA)⁴⁵.

TUNEL measurements

The aneasthetised mice were perfused tarnscardially with 4% paraformaldehyde (PFA) for 15 minutes. The brain tissue was fixed by immersion in 4% paraformaldehyde and cut into 60 μm slices. Apoptosis in ischaemic penumbra area of cerebral cortex was detected via TUNEL assay kit, as the manufacturer’s protocol. Then, the slices were stained with the neuron marker NeuN at 1:200 dilution followed by incubation with DAPI solution at 1:1000. Images were captured with a confocal scanning microscope (DMi8, Leica, Wetzlar, Germany). The apoptotic cells were calculated as a percentage of the TUNEL-positive cells in the NeuN-positive cells⁴⁹.

Infarct volume measurement

Mice were executed and each brain was cut into coronal slices (2 mm thick) with a brain-cutting matrix. The slices were stained with 1% 2,3,5-triphenyltetrazolium chloride (TTC) at 37 °C for 10 min in the dark. Normal tissues were stained (red) and infarct tissues were not stained (white). The slices were mounted to a dry black paper and photographed with a video microscopy (Chensheng Optical, Shenzhen, China). The percentage of the infarct volume in the whole brain was calculated and represented as the ischaemic extent.

Magnetic resonance imaging (MRI)

We performed in vivo MRI experiments on Signa 3.0T HDxt system (GE Healthcare, Fairfield, Connecticut, USA). Mice were anaesthetised with ketamine (80 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.) and put on an animal scanning bed. T2 weighted (T2 wt) images were collected by using a fast-spin-echo (FSE) T2-weighted sequence with the following parameters: echo time/repetition time = 85.46/ 4620 ms, field of view = 40 mm × 40 mm, 10 slices with 1.5 mm slice thickness, in-plane resolution of 512 × 512 pixel, and an imaging time of 12 minutes⁵⁴.

Behavioural tests

Mice were subjected to behavioural tests as shown in supplementary figure 1, the test sequences were randomly assigned to avoid interference from different test. Behavioural tests were recorded, stored, and analyzed by using the SMART™ tracking software program (Panlab, SL, Barcelona, Spain). The apparatus was cleaned with 25% ethanol solution after each test.

Neurological scores (NST)

To assess neurobehavioral deficits of MCAO mice, the 21 points Garcia Score were used. Neurological outcomes of mice were assessed by a blinded observer at 7 days, 14 days, 21 days and 28 days after building MCAO. The 21 points Garcia Score is a sensorimotor assessment system consisting of seven tests with scores of 0-3 for each test. These seven tests included: (i) spontaneous activity, (ii) side stroking, (iii) vibris touch, (iv) limb symmetry, (v) climbing, (vi) lateral turning, and (vii) forelimb walking⁵⁵.

Rotating rod test (RRT)

Each mouse was placed on a rotating bar, which was set to a rotation speed of up to 20 rpm during the test. The time spent on the rotating bar was recorded as the latent period. The latency before falling was recorded using a stop-watch, with a maximum of 90 seconds. Time of staying on rotating rod was used to assess motor balance ability⁵⁶.

Pole test (PT)

Each mouse was paced head-upward on the top of a vertical rough-surfaced pole (diameter 1 cm; height 55 cm). The turn downward from the top of pole (T-turn time) and the descend to the floor (T-LA) time was recorded⁵⁷.

Open field test (OFT)

The mice were pre-trained to familiar with the environment. Mice were trained at 26 and 27 days after MCAO operation. At 28 days, formal test was performed. Both in training and testing phase, each mouse was placed in an open field box (40 cm × 40 cm white floor with black plastic walls 30 cm in height) and allowed to explored for 6 minutes. Total travel distance was recorded (mm) and used to assess the capacity of mobility⁴⁶.

8 arms maze test

The maze was composed of a central platform (32 cm in diameter) from which radiated eight identical arms (50 cm long and 12 cm wide). The entrance to each arm of the maze was controlled by sliding doors that could be controlled manually by an experimenter. Each arm was terminated by a small well in which food rewards were delivered. The food rewards were single feed pallets. Mice were habituated for 2 days. During habituation, single feed pellets were placed in the small well located at the terminal ends of each arm. At the beginning of each habituation trial, mice were placed in the central platform of 8-arm maze and explored for 15 seconds. Then, all doors opened to allow mice to freely explore the maze. Mice that took all baits within a 10 minutes trial by the last day of habituation were advanced to the training phase. During training, single feed pellets were placed in terminal well of four arms (arms 2, 3, 6 and 7 in clockwise fashion). The baited arms and never-baited arms were kept constant throughout the whole training and testing phase. Working memory error (WME) is defined as re-entering the baiting arm, and reference memory error (RME) is defined as entering the non-baiting arm for the first time. If the WME frequency is zero within five consecutive training trials and the RME is one time or less, the training is considered successful. The mice were trained at 21 days after MCAO operations. Mice with or without MCAO treatments were training for 7 days and performed formal testing at 27 to 28 days after building MCAO model. WME and RME were calculated⁵⁸.

Sucrose preference test (SPT)

The sucrose preference test was performed 27 days after MCAO. After the deprivation of food and water for 12 hours, mice were provided with two pre-weighted bottles, including one bottle that contained 2.5 % sucrose solution and a second bottle filled with water, for 2 hours. The percentage preference was calculated according to the following formula: sucrose intake percentage % = [sucrose intake / (sucrose + water intake)] plus 100 %]⁵⁹.

Tail Suspension Test (TST)

Mice were suspended by their tails at 20 cm from ground for 6 minutes. The time of immobility was recorded⁴⁶.

Statistics and Reproducibility

For statistical analysis we used one-way analysis of variance (ANOVA) followed by a Tukey’s or Dunnett’s post hoc multiple comparison test for unequal replications using GraphPad Prism 8 software (GraphPad Software Inc., La Jolla, CA) and SPSS 24 software (International Business Machines Corp., NY, USA). The differences among multiple groups were analyzed by two-way ANOVA followed by a Tukey post hoc multiple comparison test. All statistical data in the text are presented as the mean ± SD, the value of significance was set at p < 0.05.

Data availability

Source data underlying the main and supplementary figures are available in Supplementary Data. The data that support the findings of this study are available from the corresponding author Baoman Li upon reasonable request.

Acknowledgments

This work was supported by the National Natural Science Foundation of China, BL [grant number 81871852]; LiaoNing Revitalization Talents Program, BL [grant number XLYC1807137], the Scientific Research Foundation for Returned Scholars of Education Ministry of China, BL [grant number 20151098], LiaoNing Thousands Talents Program, BL [grant number 202078], “ChunHui” Program of Education Ministry, BL [grant number 2020703].

Author Contributions

A.V. and B.L. designed and supervised the study; G.W., BN.C., BJ.C., M.J., H.Y., E.X. and WL.G. collected the data in vivo and analysed the relevant data; C.D., X.Z., Y.Z., M.Z., D.Z., X.W. and X.L. performed the behavioural experiments in vivo and analysed the data; B.L. and A.V. wrote the manuscript.

Competing interests

The authors have no conflicts of interest to disclose.

Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367, 1747–1757 (2006).
Benjamin, E. J. et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 137, e67–e492 (2018).
Cassidy, J.M. & Cramer, S.C. Spontaneous and therapeutic-Induced mechanisms of functional recovery after stroke. Transl. Stroke. Res. 8, 33–46 (2017).
Xu, S., Lu, J., Shao, A., Zhang, J. H., & Zhang, J. Glial Cells: Role of the Immune Response in Ischemic Stroke. Front. Immunol. 11, 294 (2020).
Makin, S. D., Turpin, S., Dennis, M. S., & Wardlaw, J. M. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes. J. Neurol. Neurosurg. Psychiatry. 84, 893–900 (2013).
Nabavi, S. F. et al. Post-Stroke Depression Modulation and in Vivo Antioxidant Activity of Gallic Acid and Its Synthetic Derivatives in a Murine Model System. Nutrients 8, 248 (2016).
Pendlebury, S. T., & Rothwell, P. M. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet. Neurol. 8, 1006–1018 (2009).
Brown, C., Hasson, H., Thyselius, V., & Almborg, A. H. Post-stroke depression and functional independence: a conundrum. Acta. Neurol. Scand. 126, 45–51 (2012).
Cook, D. J., Teves, L., & Tymianski, M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 483, 213–217 (2012).
O'Collins, V. E. et al. 1,026 experimental treatments in acute stroke. Ann. Neurol. 59, 467–477 (2006).
Johnson, F.N. The History of Lithium Therapy. London: Macmillan (1984).
Mitchell, S. W. On the use of bromide of lithium. Am. J. Med. Sci. 60, 443–445 (1870).
Hammond, W. A. A Treatise on Diseases of the Nervous System. New York: Appleton (1871).
Schou, M., Juel-Nielsen, N., Strömgren, E., Voldby, H. The treatment of manic psychoses by the administration of lithium salts. J. Neurol. Neurosurg. Psychiatr. 17, 250–260 (1954).
Shorter, E. The history of lithium therapy. Bipolar. Disord. 11 (Suppl 2), 4–9 (2009).
Dunner, D. L. Drug interactions of lithium and other antimanic/mood-stabilizing medications. J. Clin. Psychiatry 64(Suppl. 5), 38–43 (2003).
Young, W. Review of lithium effects on brain and blood. Cell. Transplant, 18, 951–975 (2009).
Chuang, D. M. et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar. Disord. 4, 129–136 (2002).
Jope, R. S. Anti-bipolar therapy: Mechanism of action of lithium. Mol. Psychiatry 4, 117–128 (1999).
Xu, J., Culman, J., Blume, A., Brecht, S., & Gohlke, P. Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke 34, 1287–1292 (2003).
Rybakowski, J. K., Suwalska, A., & Hajek, T. Clinical Perspectives of Lithium's Neuroprotective Effect. Pharmacopsychiatry 51, 194–199 (2018).
Albukrek, D., Moran, D. S., & Epstein, Y. A depressed workman with heatstroke. Lancet 347, 1016 (1996).
Allman, P., & Hawton, K. ECT for Post-stroke Depression: Beta Blockade to Modify Rise in Blood Pressure. Convuls. Ther. 3, 218–221 (1987).
Ward, R. et al. NLRP3 inflammasome inhibition with MCC950 improves diabetes-mediated cognitive impairment and vasoneuronal remodeling after ischemia. Pharmacol. Res. 142, 237–250 (2019).
Ye, Y. et al. Meisoindigo Protects Against Focal Cerebral Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Regulating Microglia/Macrophage Polarization via TLR4/NF-κB Signaling Pathway. Front. Cell. Neurosci. 13, 553 (2019).
Hong, P. et al. NLRP3 inflammasome as a potential treatment in ischemic stroke concomitant with diabetes. J. Neuroinflammation. 16, 121 (2019).
Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361 (2010).
Haneklaus, M., O'Neill, L. A., & Coll, R. C. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr. Opin. Immunol. 25, 40–45 (2013).
Chouchani, E.T. et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 515, 431–435 (2014).
Zhou, R., Yazdi, A.S., Menu, P., Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221–225 (2011).
He, W.T. et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion. Cell. Res. 25, 1285–1298 (2015).
Liu, X. et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535, 153–158 (2016).
Yang, F. et al. NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. J. Cereb. Blood. Flow. Metab. 34, 660–667 (2014).
Fann, D.Y. et al. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell. Death. Dis. 4, e790 (2013).
Hillert, M., Zimmermann, M., & Klein, J. Uptake of lithium into rat brain after acute and chronic administration. Neurosci. Lett. 521, 62–66 (2012).
Zhao, H., Sapolsky, R. M., & Steinberg, G. K. Phosphoinositide-3-kinase/akt survival signal pathways are implicated in neuronal survival after stroke. Mol Neurobiol. 34, 249–270 (2006).
Nelson, W. J., & Nusse, R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303, 1483–1487 (2004).
Biggs, W. H., 3rd, Meisenhelder, J., Hunter, T., Cavenee, W. K., & Arden, K. C. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. U. S. A. 96:7421–7426 (1999).
Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell 127, 469–480 (2006).
Kovacs, S.B. et al. Neutrophil Caspase-11 Is Essential to Defend against a Cytosol-Invasive Bacterium. Cell. Rep. 32, 107967 (2020).
Polter, A. et al. Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. Biol. Psychiatry. 65, 150–159 (2009).
Mao, Z., Liu, L., Zhang, R., & Li, X. Lithium reduces FoxO3a transcriptional activity by decreasing its intracellular content. Biol. Psychiatry. 62, 1423–1430 (2007).
Ji, Y.B. et al. Lithium alleviates blood-brain barrier breakdown after cerebral ischemia and reperfusion by upregulating endothelial Wnt/β-catenin signaling in mice. Neuropharmacology 186, 108474 (2021).
Xue, J., Jia, P., Zhang, D., & Yao, Z. TTP488 ameliorates NLRP3-associated inflammation, viability, apoptosis, and ROS production in an Alzheimer's disease cell model by mediating the JAK1/STAT3/NFκB/IRF3 pathway. Cell. Biochem. Funct. 39, 555–561 (2021).
Li, X. et al. Leptin Increases Expression of 5-HT2B Receptors in Astrocytes Thus Enhancing Action of Fluoxetine on the Depressive Behavior Induced by Sleep Deprivation. Front. Psychiatry. 9, 734 (2019).
Xia, M. et al. The ameliorative effect of fluoxetine on neuroinflammation induced by sleep deprivation. J. Neurochem. 146, 63–67 (2018).
Zhang, T., He, M. T., Zhang, X. P., Jing, L., & Zhang, J. Z. Uncoupling Protein 2 Deficiency Enhances NLRP3 Inflammasome Activation Following Hyperglycemia-Induced Exacerbation of Cerebral Ischemia and Reperfusion Damage In Vitro and In Vivo. Neurochem. Res. 46, 1359–1371 (2021).
Bi, M. et al. Bone mesenchymal stem cells transplantation combined with mild hypothermia improves the prognosis of cerebral ischemia in rats. PloS. One. 13, e0197405 (2018).
Li, B. et al. Leptin suppresses adenosine triphosphate-induced impairment of spinal cord astrocytes. J. Neurosci. Res. 94, 924–935 (2016).
, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254 (1976).
Xia, M. et al. Sleep Deprivation Selectively Down-Regulates Astrocytic 5-HT2B Receptors and Triggers Depressive-Like Behaviors via Stimulating P2X7 Receptors in Mice. Neurosci Bull. 36, 1259–1270 (2020).
Bullen, J. W. et al. Short-term resistance to diet-induced obesity in A/J mice is not associated with regulation of hypothalamic neuropeptides. Am. J. Physiol. Endocrinol. Metab.287, E662–E670 (2004).
Sun, X. L., Liu, Y., Dai, T., Ding, J. H., & Hu, G. Uncoupling protein 2 knockout exacerbates depression-like behaviors in mice via enhancing inflammatory response. Neuroscience 192, 507–514 (2011).
Yang, J. et al. Multimodality MRI assessment of grey and white matter injury and blood-brain barrier disruption after intracerebral haemorrhage in mice. Sci. Rep. 7, 40358 (2017).
Khatibi, N. H. et al. Isoflurane posttreatment reduces brain injury after an intracerebral hemorrhagic stroke in mice. Anesth. Analg. 113, 343–348 (2011).
Li, Z. et al. Fluoxetine improves behavioural deficits induced by chronic alcohol treatment by alleviating RNA editing of 5-HT2C receptors. Neurochem. Int. 134:104689 (2020).
Zhang, X., Han, T., Ding, J., & Hua, K. Split thickness skin graft for cervicovaginal reconstruction in congenital atresia of cervix. Fertil. Steril. 104, e9 (2015).
Qian, Z. J., & Ricci, A. J. Effects of cochlear hair cell ablation on spatial learning/memory. Sci. Rep. 10, 20687 (2020).
Xia, M., Yang, L., Sun, G., Qi, S., & Li, B. Mechanism of depression as a risk factor in the development of Alzheimer's disease: the function of AQP4 and the glymphatic system. Psychopharmacology, 234, 365–379 (2017).

FigureS1.tif
Supplementary Figure 1. Experimental design and drug treatments.
Mice were randomly separated into sham + normal solution (NS) group (control), sham + lithium chloride group (LiCl), MCAO + NS group (MCAO), MCAO + LiCl group, inhibitors + MCAO + NS group and inhibitors + MCAO + LiCl groups. In the last two groups, 30 minutes before the surgery, a randomly assigned mice were intraperitoneally injected with 12.5 mg/kg/day LY294002 (AKT inhibitor), 0.2 mg/kg/day PKF115584 (antagonist of β-catenin/TCF4 complex), 30 mg/kg/day WP1066 (STAT3 inhibitor) or 2.5 mg/kg/day geninpin (UCP2 inhibitor). All mice were subjected to MCAO or treated with sham operation for 60 minutes, at the middle point (30 minutes), 1 mmol/kg/day LiCl or normal saline (NS) were randomly intraperitoneal injected. After 60 minutes of ischaemia, the middle cerebral artery was reperfused, The injection of all reagents was repeated once a day for 5 days. Subsequently, 6 mice form each group were sacrificed by cervical dislocation for histology and biochemistry; remaining mice were used for behavioural tests as indicated.
FigureS2.tif
Supplementary Figure 2. Li+ suppresses expressions of NLRP3 and GSDMD induced by ischaemia-reperfusion.
Cortices of Thy1-YFP and GFAP-GFP transgenic mice were used for isolating and FACS sorting neurones and astrocytes respectively, for FACS sorting of microglia the cells from cortex of wild type mice were labelled with Iba1. (A): The representative protein bands of NRLP3, caspase-1, GSDMD, pro-caspase-1, ASC and β-actin (the house-keeping protein) in neurones, astrocytes and microglia. (B - F): Normalised intensities of NLRP3, caspase-1, GSDMD, pro-caspase-1 and ASC by β-actin are presneted as mean ± SD. N=6 per group. One-way ANOVA for comparisons including more than two groups; unpaired two-tailed t-test for two group comparisons. *p<0.05, **p<0.01, ***p<0.001.
FigureS3.tif
Supplementary Figure 3. Mechanism of Li+ action on NLRP3 and GSDMD following ischaemia-reperfusion.
(A): Representative protein bands of NRLP3, caspase-1, GSDMD, pro-caspase-1, ASC and β-actin (the house-keeping protein) in neurones, astrocytes and microglia. The normalised intensities of NLRP3, caspase-1, GSDMD, pro-caspase-1 and ASC by β-actin were shown in B-F, respectively. And the levels of IL-1β and IL-18 measured by ELISA were shown in G and H. The columns were calculated and plotted as mean ± SD. N=6 per group. One-way ANOVA for comparisons including more than two groups; unpaired two-tailed t-test for two group comparisons. *p<0.05, **p<0.01, ***p<0.001.

Download PDF

Journal Publication

published 03 Feb, 2022

Read the published version in Communications Biology →

Version 1

posted

You are reading this latest preprint version

The Neuroprotective Mechanism of Lithium after Ischaemic Stroke.

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Results

Li⁺ inhibits activation of NLRP3 inflammasome following ischaemic injury

Signalling pathways involved in Li⁺ neuroprotection

The neuroprotective effects of Li⁺ on ischaemic stroke

Discussion

methods

Declarations

References

Supplementary Files

Status:

Journal Publication

Version 1

The Neuroprotective Mechanism of Lithium after Ischaemic Stroke.

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Results

Li+ inhibits activation of NLRP3 inflammasome following ischaemic injury

Signalling pathways involved in Li+ neuroprotection

The neuroprotective effects of Li+ on ischaemic stroke

Discussion

methods

Declarations

References

Supplementary Files

Status:

Journal Publication

Version 1

Li⁺ inhibits activation of NLRP3 inflammasome following ischaemic injury

Signalling pathways involved in Li⁺ neuroprotection

The neuroprotective effects of Li⁺ on ischaemic stroke